Molecular characterisation and cetuximab-based treatment in a patient with refractory small bowel adenocarcinoma.
De Dosso
Sara
S
Molinari
Francesca
F
Martin
Vittoria
V
Frattini
Milo
M
Saletti
Piercarlo
P
D000230:Adenocarcinoma / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D017809:Fatal Outcome; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab